CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...